Literature DB >> 24481311

The role of ligand efficiency metrics in drug discovery.

Andrew L Hopkins1, György M Keserü2, Paul D Leeson3, David C Rees4, Charles H Reynolds5.   

Abstract

The judicious application of ligand or binding efficiency metrics, which quantify the molecular properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads. Retrospective analysis of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets. Optimizing ligand efficiency metrics based on both molecular mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been observed in current medicinal chemistry practice, and to increase the quality of drug candidates.

Mesh:

Substances:

Year:  2014        PMID: 24481311     DOI: 10.1038/nrd4163

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  80 in total

1.  The evolution of synthetic oral drug properties.

Authors:  John R Proudfoot
Journal:  Bioorg Med Chem Lett       Date:  2005-02-15       Impact factor: 2.823

2.  Global mapping of pharmacological space.

Authors:  Gaia V Paolini; Richard H B Shapland; Willem P van Hoorn; Jonathan S Mason; Andrew L Hopkins
Journal:  Nat Biotechnol       Date:  2006-07       Impact factor: 54.908

3.  Physiochemical drug properties associated with in vivo toxicological outcomes.

Authors:  Jason D Hughes; Julian Blagg; David A Price; Simon Bailey; Gary A Decrescenzo; Rajesh V Devraj; Edmund Ellsworth; Yvette M Fobian; Michael E Gibbs; Richard W Gilles; Nigel Greene; Enoch Huang; Teresa Krieger-Burke; Jens Loesel; Travis Wager; Larry Whiteley; Yao Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-07-24       Impact factor: 2.823

4.  The 'rule of three' for fragment-based drug discovery: where are we now?

Authors:  Harren Jhoti; Glyn Williams; David C Rees; Christopher W Murray
Journal:  Nat Rev Drug Discov       Date:  2013-07-12       Impact factor: 84.694

5.  Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.

Authors:  Tim Luker; Lilian Alcaraz; Kamaldeep K Chohan; Niklas Blomberg; Dearg S Brown; Roger J Butlin; Thomas Elebring; Andrew M Griffin; Simon Guile; Stephen St-Gallay; Britt-Marie Swahn; Steve Swallow; Michael J Waring; Mark C Wenlock; Paul D Leeson
Journal:  Bioorg Med Chem Lett       Date:  2011-07-27       Impact factor: 2.823

6.  Assessing the lipophilicity of fragments and early hits.

Authors:  Paul N Mortenson; Christopher W Murray
Journal:  J Comput Aided Mol Des       Date:  2011-05-26       Impact factor: 3.686

7.  Fragment-based lead discovery grows up.

Authors:  Monya Baker
Journal:  Nat Rev Drug Discov       Date:  2013-01       Impact factor: 84.694

8.  Thermodynamics of ligand binding and efficiency.

Authors:  Charles H Reynolds; M Katharine Holloway
Journal:  ACS Med Chem Lett       Date:  2011-03-23       Impact factor: 4.345

9.  2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: attenuation of hERG binding and improved HDLc-raising efficacy.

Authors:  Ramzi F Sweis; Julianne A Hunt; Peter J Sinclair; Ying Chen; Suzanne S Eveland; Qiu Guo; Sheryl A Hyland; Denise P Milot; Anne-Marie Cumiskey; Melanie Latham; Raymond Rosa; Larry Peterson; Carl P Sparrow; Matt S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2011-02-23       Impact factor: 2.823

Review 10.  Medicinal chemistry of Hsp90 inhibitors.

Authors:  Martin J Drysdale; Paul A Brough
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

View more
  209 in total

1.  Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.

Authors:  Wen-Hua Chen; Shan-Shan Song; Ming-Hui Qi; Xia-Juan Huan; Ying-Qing Wang; Hualiang Jiang; Jian Ding; Guo-Bin Ren; Ze-Hong Miao; Jian Li
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.

Authors:  Ping Liu; Zhiyong Hu; Byron G DuBois; Christopher R Moyes; David N Hunter; Cheng Zhu; Nam Fung Kar; Yuping Zhu; Joie Garfunkle; Ling Kang; Gary Chicchi; Anka Ehrhardt; Andrea Woods; Toru Seo; Morgan Woods; Margaret van Heek; Karen H Dingley; Jianmei Pang; Gino M Salituro; Joyce Powell; Jenna L Terebetski; Viktor Hornak; Louis-Charles Campeau; Joe Lamberson; Fez Ujjainwalla; Michael Miller; Andrew Stamford; Harold B Wood; Timothy Kowalski; Ravi P Nargund; Scott D Edmondson
Journal:  ACS Med Chem Lett       Date:  2015-07-10       Impact factor: 4.345

3.  Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site.

Authors:  Tiziana Masini; Barbara Birkaya; Simon van Dijk; Milon Mondal; Johan Hekelaar; Manuel Jäger; Anke C Terwisscha van Scheltinga; Mulchand S Patel; Anna K H Hirsch; Edelmiro Moman
Journal:  J Enzyme Inhib Med Chem       Date:  2016-07-19       Impact factor: 5.051

4.  Covalent Tethering of Fragments For Covalent Probe Discovery.

Authors:  Stefan G Kathman; Alexander V Statsyuk
Journal:  Medchemcomm       Date:  2016-01-28       Impact factor: 3.597

5.  Liganding Functional Tyrosine Sites on Proteins Using Sulfur-Triazole Exchange Chemistry.

Authors:  Jeffrey W Brulet; Adam L Borne; Kun Yuan; Adam H Libby; Ku-Lung Hsu
Journal:  J Am Chem Soc       Date:  2020-04-24       Impact factor: 15.419

6.  Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei.

Authors:  ThanhTruc Pham; Madeline Walden; Christopher Butler; Rosario Diaz-Gonzalez; Guiomar Pérez-Moreno; Gloria Ceballos-Pérez; Veronica Gomez-Pérez; Raquel García-Hernández; Henry Zecca; Emma Krakoff; Brian Kopec; Ogar Ichire; Caden Mackenzie; Marika Pitot; Luis Miguel Ruiz; Francisco Gamarro; Dolores González-Pacanowska; Miguel Navarro; Amy B Dounay
Journal:  Bioorg Med Chem Lett       Date:  2017-07-11       Impact factor: 2.823

7.  Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.

Authors:  Brendan Frett; Nick McConnell; Catherine C Smith; Yuanxiang Wang; Neil P Shah; Hong-yu Li
Journal:  Eur J Med Chem       Date:  2015-02-28       Impact factor: 6.514

8.  Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKKε for the treatment of obesity.

Authors:  Tyler S Beyett; Xinmin Gan; Shannon M Reilly; Andrew V Gomez; Louise Chang; John J G Tesmer; Alan R Saltiel; Hollis D Showalter
Journal:  Bioorg Med Chem       Date:  2018-09-20       Impact factor: 3.641

9.  A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance.

Authors:  Benjamin M Vincent; Jean-Baptiste Langlois; Raja Srinivas; Alex K Lancaster; Ruth Scherz-Shouval; Luke Whitesell; Bruce Tidor; Stephen L Buchwald; Susan Lindquist
Journal:  Cell Chem Biol       Date:  2016-08-11       Impact factor: 8.116

10.  Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.

Authors:  Katarina Roos; Anders Hogner; Derek Ogg; Martin J Packer; Eva Hansson; Kenneth L Granberg; Emma Evertsson; Anneli Nordqvist
Journal:  J Comput Aided Mol Des       Date:  2015-11-16       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.